ATR and neoplasm: Emerging evidence has shown that concurrent inhibition of Ataxia telangiectasia and Rad3-related protein (ATR) and DNA topoisomerase I (TOP1) can result in durable tumor regression in SCLC characterized by high replication stress [101].